Category: Uncategorized

Boston, Massachusetts — We are excited to announce that Quality CDMO will be attending the NACDS Total Store Expo 2026 in Boston, connecting with leading retailers, brands, suppliers, and industry professionals from across the healthcare and consumer products industry.

Visit us at Booth No. 2115 to learn more about our end-to-end OTC pharmaceutical development and manufacturing capabilities. Our team will be available to discuss your product concepts, upcoming launches, and manufacturing requirements.

At Quality CDMO, we support customers across the product lifecycle, including:

• Product Development & Formulation
• OTC Pharmaceutical Manufacturing
• Liquid & Semi-Solid Manufacturing
• Topical & Oral Care Products
• Pet Care Product Manufacturing
• Unit-Dose
• Filling & Packaging Solutions
• Scale-Up & Technology Transfer
• Quality & Analytical Support

Whether you are looking to develop a new product, reformulate an existing product, scale up production, or identify a reliable U.S. manufacturing partner, our team is ready to explore how we can support your goals.

Let’s connect at NACDS and explore opportunities to bring your next product to market.

📍 Booth: 2115
📅 NACDS Total Store Expo 2026
📍 Boston, Massachusetts

We look forward to meeting you in Boston!

Fort Worth, Texas – Quality CDMO has successfully completed an FDA inspection with zero observations issued, reflecting the strength of our quality systems, manufacturing practices, and commitment to cGMP compliance.

This achievement reinforces our focus on maintaining a consistent culture of quality, compliance, and operational excellence across every stage of our manufacturing operations. Our quality systems are supported by robust procedures, comprehensive documentation, effective process controls, trained personnel, and ongoing oversight.

We continuously evaluate and strengthen our processes through risk-based quality management, CAPA, deviation management, change control, supplier qualification, and continuous improvement initiatives.

For our customers, this provides confidence that their products are being developed and manufactured within a quality-driven and compliance-focused environment.

Quality is not just a requirement at Quality CDMO—it is built into everything we do.

Texas – When people think of pharmaceutical hubs, they usually think of Boston, San Francisco, or New Jersey. But Texas is quietly—and rapidly—disrupting the entire domestic bio-manufacturing landscape.

From specialized cell therapies to high-purity plasmid DNA and massive large-molecule plants, the Lone Star State is experiencing an unprecedented infrastructure wave. The combination of lower operating costs, a strong talent pool, world-class research institutions, business-friendly policies, and significant investment in advanced manufacturing is attracting both established pharmaceutical companies and emerging biotech firms.

Texas is no longer simply a location for large-scale manufacturing. It is developing a full life-sciences ecosystem, spanning early-stage development, process development, clinical manufacturing, commercial production, analytical testing, and specialized packaging.

Why Texas Is Becoming a Major CDMO Hub

Several factors are accelerating Texas’ growth as a pharmaceutical manufacturing destination:

• Strategic location and logistics — Texas provides access to major transportation networks and large domestic markets.
• Expanding life-sciences workforce — Universities and research centers across the state are producing a growing pool of scientific and technical talent.
• Large-scale manufacturing infrastructure — The state has attracted significant investment in advanced biologics and pharmaceutical manufacturing facilities.
• Growing biotech ecosystem — Cities including Houston, Dallas–Fort Worth, Austin, and San Antonio are developing distinct strengths across biotechnology and healthcare.
• Cost advantages — Compared with traditional pharmaceutical hubs, Texas can offer competitive real-estate, labor, and operating costs.
• End-to-end capabilities — Companies operating in Texas increasingly support projects from development and clinical manufacturing through commercial scale.